High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci184283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Harun Ozturk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, I…. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Kelch-Like ECH-Associated Protein 1, Drug Resistance, Neoplasm, Ovarian Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Protein arginine methyl transferases (PRMTs) are generally upregulated in cancers. However, the mechanisms leading to this upregulation and its biological consequences are poorly understood. Here, we identify PRMT5, the main symmetric arginine methyltransferase, as a critical driver of chemoresistance in high-grade serous ovarian cancer (HGSOC). PRMT5 levels and its enzymatic activity are induced in a platinum-resistant (Pt-resistant) state at the protein level. To reveal potential regulators of high PRMT5 protein levels, we optimized intracellular immunostaining conditions and performed unbiased CRISPR screening. We identified Kelch-like ECH-associated protein 1 (KEAP1) as a top-scoring negative regulator of PRMT5. Our mechanistic studies show that KEAP1 directly interacted with PRMT5, leading to its ubiquitin-dependent degradation under normal physiological conditions. At the genomic level, ChIP studies showed that elevated PRMT5 directly interacted with the promoters of stress response genes and positively regulated their transcription. Combined PRMT5 inhibition with Pt resulted in synergistic cellular cytotoxicity in vitro and reduced tumor growth in vivo in Pt-resistant patient-derived xenograft tumors. Overall, the findings from this study identify PRMT5 as a critical therapeutic target in Pt-resistant HGSOC cells and reveal the molecular mechanisms that lead to high PRMT5 levels in Pt-treated and chemo-resistant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, Illinois, USA.
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Ozturk, H., Seker-Polat, F., Abbaszadeh, N., Kingham, Y., Orsulic, S., & Adli, M. (2025). High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci184283
Vancouver
Ozturk H, Seker-Polat F, Abbaszadeh N, Kingham Y, Orsulic S, Adli M. High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci184283
BibTeX
@article{Ozturk2025,
author = {Ozturk, Harun and Seker-Polat, Fidan and Abbaszadeh, Neda and Kingham, Yasemin and Orsulic, Sandra and Adli, Mazhar},
title = {High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci184283}
}
EUVIMED